This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ivan S. Login, MD
Department of Neurology University of Virginia School of Medicine Box 394 Charlottesville, VA 22908

Arch Neurol. 1988;45(8):831-832.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—This is a letter describing an unfavorable clinical response in one woman to the new, pink Tegretol (carbamazepine) tablets. It is not possible to ascertain whether this is a unique observation, but the clinical report may be of benefit to others using Tegretol.

Report of a Case.

—A 46-year-old woman with chronic asthma experienced recurrent episodes of loss of consciousness with urinary incontinence. In 1985, these episodes were diagnosed as epilepsy and she was treated successfully with Tegretol. Tegretol therapy was subsequently discontinued by another physician and her episodes of unconsciousness and urinary incontinence returned. When evaluated again in 1987 for the neurologic problem, Tegretol therapy was reinstituted. At this time, however, the manufacturer had replaced the original, white tablets with the new pink variety. The patient noted that within a few hours of ingesting each 200-mg pink tablet, she would experience a constellation of symptoms that . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?